GROUP 1 - Drug program: Treatment of chronic Hepatitis B

This tender concerns Group 1 of a drug program focused on the treatment of chronic Hepatitis B. The specific requirement detailed is for the supply of Tenofovir disoproxil 245mg tablets, with each package containing 30 film-coated tablets. The program aims to provide essential medication for patients suffering from chronic Hepatitis B, a significant public health concern. The procurement is likely part of a broader healthcare initiative to ensure access to effective treatments for viral hepatitis. The tender specifies the exact pharmaceutical product and dosage form required, indicating a need for a precise and reliable supply chain. Further details regarding the scope of the program, including the number of patients to be treated, the duration of the supply contract, and specific quality standards for the medication, are expected to be outlined in the full tender documentation. This initiative underscores the commitment to managing and treating chronic Hepatitis B within the healthcare system, ensuring that patients receive necessary therapeutic interventions. The focus on a specific antiviral medication suggests a targeted approach to managing this condition, aiming for improved patient outcomes and disease control.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals and Infectious Diseases. Located in Poland, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.